181 related articles for article (PubMed ID: 17340468)
1. Single-chain antibodies as new antithrombotic drugs.
Hagemeyer CE; Schwarz M; Peter K
Semin Thromb Hemost; 2007 Mar; 33(2):185-95. PubMed ID: 17340468
[TBL] [Abstract][Full Text] [Related]
2. [Helping antibodies. Targeted antithrombotic and fibrinolytic therapy].
Schwarz M; Hagemeyer CE; Peter K; Bode C
Hamostaseologie; 2007 Dec; 27(5):360-2. PubMed ID: 18060247
[TBL] [Abstract][Full Text] [Related]
3. Single-chain antibodies as diagnostic tools and therapeutic agents.
Hagemeyer CE; von Zur Muhlen C; von Elverfeldt D; Peter K
Thromb Haemost; 2009 Jun; 101(6):1012-9. PubMed ID: 19492141
[TBL] [Abstract][Full Text] [Related]
4. Applications of single-chain variable fragment antibodies in therapeutics and diagnostics.
Weisser NE; Hall JC
Biotechnol Adv; 2009; 27(4):502-20. PubMed ID: 19374944
[TBL] [Abstract][Full Text] [Related]
5. Tailor-made antibody therapeutics.
Chowdhury PS; Wu H
Methods; 2005 May; 36(1):11-24. PubMed ID: 15848071
[TBL] [Abstract][Full Text] [Related]
6. Glycosylation of recombinant antibody therapeutics.
Jefferis R
Biotechnol Prog; 2005; 21(1):11-6. PubMed ID: 15903235
[TBL] [Abstract][Full Text] [Related]
7. Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design.
Deyev SM; Lebedenko EN
Bioessays; 2008 Sep; 30(9):904-18. PubMed ID: 18693269
[TBL] [Abstract][Full Text] [Related]
8. Antibody engineering: facing new challenges in cancer therapy.
Sanz L; Cuesta AM; Compte M; Alvarez-Vallina L
Acta Pharmacol Sin; 2005 Jun; 26(6):641-8. PubMed ID: 15916728
[TBL] [Abstract][Full Text] [Related]
9. Engineered single chain antibody fragments for radioimmunotherapy.
Huhalov A; Chester KA
Q J Nucl Med Mol Imaging; 2004 Dec; 48(4):279-88. PubMed ID: 15640791
[TBL] [Abstract][Full Text] [Related]
10. Antibody therapeutics, antibody engineering, and the merits of protein stability.
Demarest SJ; Glaser SM
Curr Opin Drug Discov Devel; 2008 Sep; 11(5):675-87. PubMed ID: 18729019
[TBL] [Abstract][Full Text] [Related]
11. Production of antibody fragments in Arabidopsis seeds.
Van Droogenbroeck B; De Wilde K; Depicker A
Methods Mol Biol; 2009; 483():89-101. PubMed ID: 19183895
[TBL] [Abstract][Full Text] [Related]
12. Antibodies and gene therapy: teaching old 'magic bullets' new tricks.
Sanz L; Blanco B; Alvarez-Vallina L
Trends Immunol; 2004 Feb; 25(2):85-91. PubMed ID: 15102367
[TBL] [Abstract][Full Text] [Related]
13. Potent antibody therapeutics by design.
Carter PJ
Nat Rev Immunol; 2006 May; 6(5):343-57. PubMed ID: 16622479
[TBL] [Abstract][Full Text] [Related]
14. Nanobodies in therapeutic applications.
Roovers RC; van Dongen GA; van Bergen en Henegouwen PM
Curr Opin Mol Ther; 2007 Aug; 9(4):327-35. PubMed ID: 17694445
[TBL] [Abstract][Full Text] [Related]
15. Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays.
Golay J; Introna M
Arch Biochem Biophys; 2012 Oct; 526(2):146-53. PubMed ID: 22387378
[TBL] [Abstract][Full Text] [Related]
16. Engineered antibody fragments and the rise of single domains.
Holliger P; Hudson PJ
Nat Biotechnol; 2005 Sep; 23(9):1126-36. PubMed ID: 16151406
[TBL] [Abstract][Full Text] [Related]
17. Alternative antibody formats.
Kontermann RE
Curr Opin Mol Ther; 2010 Apr; 12(2):176-83. PubMed ID: 20373261
[TBL] [Abstract][Full Text] [Related]
18. The human combinatorial antibody library HuCAL GOLD combines diversification of all six CDRs according to the natural immune system with a novel display method for efficient selection of high-affinity antibodies.
Rothe C; Urlinger S; Löhning C; Prassler J; Stark Y; Jäger U; Hubner B; Bardroff M; Pradel I; Boss M; Bittlingmaier R; Bataa T; Frisch C; Brocks B; Honegger A; Urban M
J Mol Biol; 2008 Feb; 376(4):1182-200. PubMed ID: 18191144
[TBL] [Abstract][Full Text] [Related]
19. The development of nanobodies for therapeutic applications.
Van Bockstaele F; Holz JB; Revets H
Curr Opin Investig Drugs; 2009 Nov; 10(11):1212-24. PubMed ID: 19876789
[TBL] [Abstract][Full Text] [Related]
20. Recombinant bispecific single chain antibody fragments induce Fc gamma-receptor-mediated elimination of CD30+ lymphoma cells.
Ranft K; Thepen T; Fischer R; Barth S; Stöcker M
Cancer Lett; 2009 Sep; 282(2):187-94. PubMed ID: 19345477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
